Bernard A Fox, Co-founder, President and CEO of UbiVac, shared a post on LinkedIn:
“FANTASTIC meeting this morning with Prof. Taha Merghoub at Meyer Cancer Center Weill Cornell Medicine and his colleagues Drs. Rachana Maniyar and Lucia Morgado Palacin.
We compared their findings in preclinical models with combinations of antibodies to GITR, LAG3, and PD1 and our findings from Rom Leidner‘s clinical trials where patients received vaccine (DPV001) and anti-PD-1 +/- anti-GITR and LAG3 expression was evaluated.
Think between Taha’s group and mine at Earle A. Chiles Research Institute / Providence Cancer Institute we have insights that we will soon share in publications, but would benefit from additional samples from patients that received anti-GITR.
If you have such samples, we would be interested in connecting..”
Proceed to the video attached to the post.
More posts featuring Bernard A Fox